SCHEMBL3969727

SCHEMBL3969727

COn1cnc2ncccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.45
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.38
LTA4H P09960 1/20 0.38
HIF1A Q16665 1/20 0.37
ALDH1A1 P00352 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
MAPK14 Q16539 1/20 0.32
RPS6KA5 O75582 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10696473 0.80 LTA4H (0.39) BACE1KMT2ANPC1RAB9AL3MBTL1
SCHEMBL10695888 0.78 LTA4H (0.40) BACE1KMT2ANPC1RAB9AL3MBTL1
SCHEMBL10695851 0.76 PDE5A (0.36) BACE1KMT2ANPC1RAB9AL3MBTL1
SCHEMBL256361 0.74 LTA4H (0.41) BACE1KMT2ANPC1RAB9ALTA4H
SCHEMBL30178291 0.74 LTA4H (0.41) BACE1KMT2ANPC1RAB9ALTA4H
SCHEMBL14763692 0.73 LTA4H (0.48) BACE1KMT2ANPC1RAB9AL3MBTL1
SCHEMBL10697815 0.73 LTA4H (0.36) BACE1LTA4HMKNK1MKNK2MAPK14
SCHEMBL31229913 0.71 LTA4H (0.39) BACE1KMT2ANPC1RAB9ALTA4H
SCHEMBL1165560 0.69 LTA4H (0.38) BACE1KMT2ANPC1RAB9ALTA4H
SCHEMBL13378103 0.69 RPS6KA5 (0.38) BACE1KMT2ANPC1RAB9ALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
WO-2003040103-A1 β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 BACE1 72/4885KMT2A 3445/4885NPC1 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.